Recruiting

Travoprost Intraocular Implant + iStent Infinite

Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.

ClinicalTrials.gov IDNCT06066645

PhasePHASE4

Enrollment150

SponsorGlaukos Corporation

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Glaucoma, Open-Angle

About this study

Interventions

Drug: Travoprost Intraocular Implant — anchored intracameral implant containing travoprost
Device: iStent infinite — Successful iStent infinite surgery
Other: Sham procedure — Sham procedure (to mimic placement of an iStent infinite)

Primary outcomes

change from baseline in mean diurnal intraocular pressure (IOP) (3 months)

Eligibility information

Inclusion Criteria: * diagnosis of open-angle glaucoma or ocular hypertension * qualifying IOP in the study eye Exclusion Criteria: * unmedicated (washed out) IOP of \>36 mmHg in the study eye * hypersensitivity to travoprost or any other components of the travoprost intraocular implant * vertical cup/disc ratio \> 0.8 in the study eye * best spectacle corrected visual acuity of worse than 20/80 in either eye * any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Study locations

Glaukos Clinical Study Site, Oklahoma City, Oklahoma 73112 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.